Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | LPL | P06858 | 3/20 | 0.42 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MPI | P34949 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 3/20 | 0.36 |
| ▸ | TRPM4 | Q8TD43 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | JAK2 | O60674 | 1/20 | 0.32 |
| ▸ | BTK | Q06187 | 1/20 | 0.32 |
| ▸ | P4HB | P07237 | 1/20 | 0.31 |
| ▸ | ANPEP | P15144 | 1/20 | 0.31 |
| ▸ | LAP3 | P28838 | 1/20 | 0.31 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21459066 | 1.00 | NQO2 (0.46) | NQO2LPLLIPGKDM4EMEN1 | |
| SCHEMBL29964335 | 0.94 | NQO2 (0.41) | NQO2LPLLIPGKDM4EMEN1 | |
| SCHEMBL24680593 | 0.84 | NQO2 (0.38) | NQO2LPLLIPGKDM4EMEN1 | |
| SCHEMBL23569435 | 0.83 | ESR1 (0.39) | NQO2LPLLIPGCYP1A2JAK2 | |
| SCHEMBL29478942 | 0.83 | ESR1 (0.39) | NQO2LPLLIPGCYP1A2JAK2 | |
| SCHEMBL20017911 | 0.82 | CYP1A2 (0.47) | LPLLIPGKDM4EMEN1ALDH1A1 | |
| SCHEMBL22555118 | 0.82 | LPL (0.43) | LPLLIPGKDM4EALDH1A1MAPT | |
| SCHEMBL30065204 | 0.82 | LPL (0.43) | LPLLIPGKDM4EALDH1A1MAPT | |
| SCHEMBL734336 | 0.81 | LPL (0.45) | LPLLIPGALDH1A1MAPTHPGD | |
| SCHEMBL23569463 | 0.81 | LPL (0.34) | LPLLIPGKDM4EALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4612155-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | AMGEN INC. (US) | 2025-06-05 | — | — | US | disclosed |
| CN-119954832-A | KRAS small molecule fluorescent probe and preparation method and application thereof | 中国药科大学 | 2025-05-09 | — | — | CN | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122222-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-4415824-A1 | QUINOLINE COMPOUNDS AS INHIBITORS OF KRAS | Incyte Corporation (US) | 2024-08-21 | — | — | EP | disclosed |
| EP-4405337-A1 | FUSED PYRIMIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | Beta Pharma, Inc. (US) | 2024-07-31 | — | — | EP | disclosed |
| WO-2024097559-A1 | 1,5-NAPHTHYRIDINE DERIVATIVES AS KRAS ONCOPROTEIN INHIBITORS | BETA PHARMA, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| EP-4363412-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Dana-Farber Cancer Institute, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2024083168-A1 | OXAZEPINE COMPOUNDS COMPRISING A 6-AZA MOIETY AND USES THEREOF | GENENTECH, INC. (US) | 2024-04-25 | — | — | WO | disclosed |
| WO-2022192794-A1 | KRAS G12D INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-115003677-A | Compounds having inhibitory activity against KRAS G12D mutation | 大鹏药品工业株式会社 | 2022-09-02 | — | — | CN | disclosed |
| CN-114828964-A | KRAS G12C inhibitors | 伊莱利利公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022098625-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-05-12 | — | — | WO | disclosed |
| CN-112805281-B | KRAS G12C inhibitors | 伊莱利利公司 | 2022-05-10 | — | — | CN | disclosed |
| WO-2022083569-A1 | HETEROCYCLIC SPIRO COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022068921-A1 | QUINAZOLINE COMPOUND AND APPLICATION THEREOF | 上海医药集团股份有限公司 | 2022-04-07 | — | — | WO | disclosed |
| WO-2022047093-A1 | VINYL IMIDAZOLE COMPOUNDS AS INHIBITORS OF KRAS | INCYTE CORPORATION (US) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022042630-A1 | HETEROARYL COMPOUNDS, PREPARATION METHODS AND USES THEREOF | InventisBio Co., Ltd. (CN) | 2022-03-03 | — | — | WO | disclosed |
| WO-2022031678-A1 | KRAS G12D INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250179077-A1 | QUINAZOLINE COMPOUNDS AND USES THEREOF AS INHIBITORS OF MUTANT KRAS PROTEINS | KRAS, NRAS, HRAS | NQO2 56/4885LPL 4612/4885LIPG 3779/4885 |
| US-20250122222-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE | KRAS, NRAS, HRAS | NQO2 178/4885LPL 4702/4885LIPG 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.